Cyclopharm (ASX:CYC)
Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.
11/10/2023 Finally FDA approved
27/04/2023 Clock’s ticking
24/06/2022 Set for a good year, even with FDA approval taking a bit longer
01/03/2022 FDA approval is last piece of the puzzle
Check out our interview with CEO James McBrayer (4 April 2023)